share_log

FDA Reviews Shin Nippon Biomedical Laboratories' Resubmitted NDA for Migraine Treatment STS101

FDA Reviews Shin Nippon Biomedical Laboratories' Resubmitted NDA for Migraine Treatment STS101

美国食品药品监督管理局审查了新日本生物医药实验室重新提交的用于治疗偏头痛的STS101新药申请
MT Newswires ·  2024/11/26 03:52

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发